Potential for reducing resting sympathetic nerve activity with new classes of glucose-lowering drugs in heart failure with preserved ejection fraction

Clin Auton Res. 2024 Feb;34(1):223-226. doi: 10.1007/s10286-023-01013-0. Epub 2024 Jan 29.

Takuro Washio^#^{1

2}, Sarah L Hissen^#^{1

2}, Ryosuke Takeda^{1

2}, John D Akins^{1

2}, Denis J Wakeham^{1

2}, Tiffany Brazile^{1

2}, Christopher M Hearon Jr^{1

2}, James P MacNamara^{1

2}, Satyam Sarma^{1

2}, Benjamin D Levine^{1

2}, Paul J Fadel³, Qi Fu^{4

5}

¹ Institute for Exercise and Environmental Medicine at Texas Health Presbyterian Hospital Dallas, 7232 Greenville Ave., Ste. 435, Dallas, TX, 75231-8205, USA.
² University of Texas Southwestern Medical Center, Dallas, TX, USA.
³ University of Texas at Arlington, Arlington, TX, USA.
⁴ Institute for Exercise and Environmental Medicine at Texas Health Presbyterian Hospital Dallas, 7232 Greenville Ave., Ste. 435, Dallas, TX, 75231-8205, USA. qifu@TexasHealth.org.
⁵ University of Texas Southwestern Medical Center, Dallas, TX, USA. qifu@TexasHealth.org.

^# Contributed equally.

No abstract available

Keywords: Glucagon-like peptide 1 receptor agonists; Muscle sympathetic nerve activity; Sodium–glucose cotransporter 2 inhibitors; Weight loss.

Publication types